Literature DB >> 32556443

Anti-tumor efficacy of plasmid encoding emm55 in a murine melanoma model.

Brittany L Bunch1, Krithika N Kodumudi1, Ellen Scott1, Jennifer Morse1, Amy Mackay Weber1, Anders E Berglund2,3, Shari Pilon-Thomas4,5,6,7, Joseph Markowitz8,9,10.   

Abstract

Emm55 is a bacterial gene derived from Streptococcus pyogenes (S. pyogenes) that was cloned into a plasmid DNA vaccine (pAc/emm55). In this study, we investigated the anti-tumor efficacy of pAc/emm55 in a B16 murine melanoma model. Intralesional (IL) injections of pAc/emm55 significantly delayed tumor growth compared to the pAc/Empty group. There was a significant increase in the CD8+ T cells infiltrating into the tumors after pAc/emm55 treatment compared to the control group. In addition, we observed that IL injection of pAc/emm55 increased antigen-specific T cell infiltration into tumors. Depletion of CD4+ or CD8+ T cells abrogated the anti-tumor effect of pAc/emm55. Combination treatment of IL injection of pAc/emm55 with anti-PD-1 antibody significantly delayed tumor growth compared to either monotherapy. pAc/emm55 treatment combined with PD-1 blockade enhanced anti-tumor immune response and improved systemic anti-tumor immunity. Together, these strategies may lead to improvements in the treatment of patients with melanoma.

Entities:  

Keywords:  Bacterial protein; Intralesional injection; Melanoma; Streptococcus pyogenes; emm55

Year:  2020        PMID: 32556443      PMCID: PMC7680263          DOI: 10.1007/s00262-020-02634-4

Source DB:  PubMed          Journal:  Cancer Immunol Immunother        ISSN: 0340-7004            Impact factor:   6.968


  39 in total

Review 1.  Bacterial proteins and CpG-rich extrachromosomal DNA in potential cancer therapy.

Authors:  Magdy Mahfouz; Wataru Hashimoto; Tapas K Das Gupta; Ananda M Chakrabarty
Journal:  Plasmid       Date:  2006-12-12       Impact factor: 3.466

2.  Bacillus Calmette-Guérin treatment and vesicorenal reflux.

Authors:  A Böhle; J Schüller; A Knipper; A Hofstetter
Journal:  Eur Urol       Date:  1990       Impact factor: 20.096

3.  Intralesional PV-10 for in-transit melanoma-A single-center experience.

Authors:  Jocelyn Lippey; Rhiannon Bousounis; Cori Behrenbruch; Bartholomew McKay; John Spillane; Michael A Henderson; David Speakman; David E Gyorki
Journal:  J Surg Oncol       Date:  2016-05-30       Impact factor: 3.454

4.  Talimogene Laherparepvec Improves Durable Response Rate in Patients With Advanced Melanoma.

Authors:  Robert H I Andtbacka; Howard L Kaufman; Frances Collichio; Thomas Amatruda; Neil Senzer; Jason Chesney; Keith A Delman; Lynn E Spitler; Igor Puzanov; Sanjiv S Agarwala; Mohammed Milhem; Lee Cranmer; Brendan Curti; Karl Lewis; Merrick Ross; Troy Guthrie; Gerald P Linette; Gregory A Daniels; Kevin Harrington; Mark R Middleton; Wilson H Miller; Jonathan S Zager; Yining Ye; Bin Yao; Ai Li; Susan Doleman; Ari VanderWalde; Jennifer Gansert; Robert S Coffin
Journal:  J Clin Oncol       Date:  2015-05-26       Impact factor: 44.544

5.  Blockade of myeloid-derived suppressor cells after induction of lymphopenia improves adoptive T cell therapy in a murine model of melanoma.

Authors:  Krithika N Kodumudi; Amy Weber; Amod A Sarnaik; Shari Pilon-Thomas
Journal:  J Immunol       Date:  2012-10-24       Impact factor: 5.422

6.  Immune Checkpoint Blockade to Improve Tumor Infiltrating Lymphocytes for Adoptive Cell Therapy.

Authors:  Krithika N Kodumudi; Jessica Siegel; Amy M Weber; Ellen Scott; Amod A Sarnaik; Shari Pilon-Thomas
Journal:  PLoS One       Date:  2016-04-06       Impact factor: 3.240

Review 7.  Promising Targets for Cancer Immunotherapy: TLRs, RLRs, and STING-Mediated Innate Immune Pathways.

Authors:  Kai Li; Shuai Qu; Xi Chen; Qiong Wu; Ming Shi
Journal:  Int J Mol Sci       Date:  2017-02-14       Impact factor: 5.923

8.  Type I Interferon-Independent Dendritic Cell Priming and Antitumor T Cell Activation Induced by a Mycoplasma fermentans Lipopeptide.

Authors:  Yohei Takeda; Masahiro Azuma; Kenji Funami; Hiroaki Shime; Misako Matsumoto; Tsukasa Seya
Journal:  Front Immunol       Date:  2018-03-14       Impact factor: 7.561

9.  Intralesional injection of rose bengal induces a systemic tumor-specific immune response in murine models of melanoma and breast cancer.

Authors:  Paul Toomey; Krithika Kodumudi; Amy Weber; Lisa Kuhn; Ellen Moore; Amod A Sarnaik; Shari Pilon-Thomas
Journal:  PLoS One       Date:  2013-07-17       Impact factor: 3.240

Review 10.  Application potential of toll-like receptors in cancer immunotherapy: Systematic review.

Authors:  Ming Shi; Xi Chen; Kangruo Ye; Yuanfei Yao; Yu Li
Journal:  Medicine (Baltimore)       Date:  2016-06       Impact factor: 1.889

View more
  1 in total

1.  Electroporation outperforms in vivo-jetPEI for intratumoral DNA-based reporter gene transfer.

Authors:  Liesl Jacobs; Elien De Smidt; Nick Geukens; Paul Declerck; Kevin Hollevoet
Journal:  Sci Rep       Date:  2020-11-11       Impact factor: 4.379

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.